Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 101 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: risperidone (Risperdal) Clear all
Not listed Phase 4 Interventional

Effectiveness of Combined Medication Treatment for Aggression in Children With Attention Deficit With Hyperactivity Disorder (The SPICY Study)

NCT00794625
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Valproate, Risperidone, Placebo, Stimulant medication, Behavioral family counseling
Drug · Behavioral
Lead sponsor
Joseph Blader
NIH
Eligibility
6 Years to 12 Years
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Glen Oaks, New York • Stony Brook, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 4, 2026, 8:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Glutamate, Brain Connectivity and Duration of Untreated Psychosis

NCT02034253
View directory record Official record
Conditions
Schizophrenia, Psychosis, Schizoaffective Disorder
Interventions
Risperidone
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
17 Years to 35 Years
Enrollment
134 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Reducing the Abuse Liability of Prescription Opioids

NCT04587115
View directory record Official record
Conditions
Addiction
Interventions
Risperidone, Ziprasidone, Oxycodone
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
21 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2020 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder

NCT02186769
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal® Consta®, LY03004
Drug
Lead sponsor
Luye Pharma Group Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Orange County, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 18, 2015 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Comparative Bioavailability of Risperidone.

NCT05179525
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM® 100 mg, Risperdal 4mg Tablet
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Garden Grove, California • Gaithersburg, Maryland • Berlin, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2022 · Synced Oct 4, 2026, 8:08 AM EDT
Withdrawn Not applicable Interventional

Impulsivity and Thought Process Disorder in Patients With Active Suicidal Ideation and Depression

NCT01770600
View directory record Official record
Conditions
Impulsivity, Active Suicidal Ideation, Depression
Interventions
placebo, Riperidone
Other · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 3 Interventional

Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005

NCT05779241
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
LYN-005, Risperidone
Drug
Lead sponsor
Lyndra Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
5
States / cities
Garden Grove, California • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis

NCT00320671
View directory record Official record
Conditions
Schizophrenia
Interventions
Aripiprazole, Risperidone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and the Effects of Risperidone Compared With Other Atypical Antipsychotic Drugs on the Growth and Sexual Maturation in Children

NCT01050582
View directory record Official record
Conditions
Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
Interventions
Risperidone, Other atypical antipsychotic drugs
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
8 Years to 16 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
13
States / cities
San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism

NCT02237417
View directory record Official record
Conditions
Schizophrenia
Interventions
Standard of Care Oral antipsychotics, IM aripiprazole once monthly, No Treatment
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 4, 2026, 8:08 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (New Use) Weight Loss Study

NCT01272752
View directory record Official record
Conditions
Obesity
Interventions
IHBG-10, Placebo
Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Paliperidone Palmitate and RISPERDAL CONSTA in Patients With Schizophrenia

NCT00589914
View directory record Official record
Conditions
Schizophrenia
Interventions
RISPERDAL CONSTA, Paliperidone palmitate
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
1,221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
15
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2014 · Synced Oct 4, 2026, 8:08 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

National Pregnancy Registry for Psychiatric Medications

NCT01246765
View directory record Official record
Conditions
Pregnant Women, Psychotropic Drugs
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2033
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 24, 2025 · Synced Oct 4, 2026, 8:08 AM EDT
Withdrawn Phase 2 Interventional

Anti-psychotic Medication (Stable Dose) Weight Loss Study

NCT01272765
View directory record Official record
Conditions
Obesity
Interventions
Placebo, IHBG-10
Other · Dietary Supplement
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Metabolic Effects of Antipsychotics in Children

NCT00205699
View directory record Official record
Conditions
Aggression, Attention Deficit-Hyperactivity, Oppositional Defiant Disorder, Pervasive Development Disorders, Bipolar Disorder
Interventions
risperidone, olanzapine, aripiprazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Years to 18 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 15, 2018 · Synced Oct 4, 2026, 8:08 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Striatal Connectivity and Clinical Outcome in Psychosis

NCT02822092
View directory record Official record
Conditions
Psychotic Disorders
Interventions
Risperidone or Aripiprazole (patients only)
Drug
Lead sponsor
Northwell Health
Other
Eligibility
15 Years to 40 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2024 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Treatment of Severe Childhood Aggression (The TOSCA Study)

NCT00796302
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo
Drug · Behavioral
Lead sponsor
Michael Aman
Other
Eligibility
6 Years to 12 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
4
States / cities
Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2017 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia

NCT00330551
View directory record Official record
Conditions
Schizophrenia
Interventions
Oral Risperidone, Risperidone in Long-Acting Injectable Form (Consta)
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 3 Interventional

Effects of Risperdal Consta on Ability to Benefit From Social Skills Training in Schizophrenia

NCT00148083
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperdal Consta (drug), Social Skills Training
Drug · Behavioral
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
2
States / cities
Chicago, Illinois • White Plains, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2019 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Side Effects of Newer Antipsychotics in Older Adults

NCT00245206
View directory record Official record
Conditions
Schizophrenia, Alzheimer's Disease, Dementia
Interventions
Aripiprazole, Olanzapine, Risperidone
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional

Improving Work Outcome in People With Recent-onset Schizophrenia

NCT00203788
View directory record Official record
Conditions
Schizophrenia
Interventions
Individual Placement and Support, Workplace Fundamentals Module, Brokered Vocational Rehabilitation, Oral risperidone, Skills training group
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia

NCT01175135
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-02545920, Placebo, Risperidone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
38
States / cities
Little Rock, Arkansas • Anaheim, California • Escondido, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 22, 2018 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Not applicable Interventional

A Randomized Control Trial Comparing Quetiapine to Risperidone in Bipolar Disorder With Stimulant Dependence

NCT00227123
View directory record Official record
Conditions
Bipolar Disorder, Cocaine Dependence, Methamphetamine Dependence
Interventions
quetiapine, risperidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Dallas, Texas • Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2008 · Synced Oct 4, 2026, 8:08 AM EDT
Completed Phase 4 Interventional Results available

Comparison of Antipsychotics for Metabolic Problems in Schizophrenia or Schizoaffective Disorder

NCT00423878
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Risperidone, Olanzapine, Quetiapine, Aripiprazole
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
28
States / cities
Colton, California • Palo Alto, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 4, 2026, 8:08 AM EDT